David Drutz, MD
Elected 1979

President, Pacific Biopharma Associates. Biotech Consulting (1999-present). Director, Altimmune, Inc (ALT:Nasdaq). Metabolic Diseases/Obesity (2007-present). CEO/CMO/Executive Chairman, DARA Biosciences (Nasdaq). Oncology Supportive Care  (2011-2015). Genome Canada Scientific and Industry Advisory Committee/SIAC (2007-2014). Director, Gentris Corporation. Oncology-Focused Pharmacogenomics (2007-2014). Chairman, Tranzyme, Inc. GI Diseases (2000-2010). Director, MethylGene Inc (TSX). Epigenetics/Oncology (2000-2010). General Partner, Pacific Rim Ventures, Tokyo. Global Biotechnology Investments (1999-2008). CEO, Inspire Pharmaceuticals. Cystic Fibrosis/COPD (1995-1998). CEO, Sennes Drug Innovations. Oncology Supportive Care; Adj Prof Microbiology, Baylor Coll Med (1994-1995). VP Clinical Development, Daiichi Pharmaceutical Corporation; Clin Prof Medicine, Seaton Hall U Sch Grad Med; Adj Prof Microbiology, Temple Univ Sch Med (1990-1994). VP Biological Sciences/VP Clinical Research. Smith Kline & French Laboratories; Adj Prof Medicine U Penn. Adj Prof Microbiology Temple Univ Sch Med (1986-1990). Founder & Director, Center for Cell Regulation: NSF Industry-University Cooperative Research Center/IUCRC (UTHSCSA 1984-1986). Professor Medicine/Professor Microbiology; Chief of Infectious Diseases. UT Health Science Center, San Antonio (1975-1986). Assistant Professor Medicine; Chief of Infectious Diseases/SFGH; Research Associate, Cancer Research Institute, UCSF (1969-1974). LCDR/MC/USNR. Taiwan, Vietnam & Philippines (1967-1969). USPHS postdoctoral ID fellowship, Vanderbilt University (1965-1967). Internal Medicine Residency, Vanderbilt (1963-1965). Internship, University of Louisville (1962-1963). MD, University of Louisville (1962); BA (1958). AOA, FACP, FIDSA, ASCI, ASCO, ASM, AMA, AAAS, MASCC/ISOO. 100+ peer-reviewed publications + 13 issued patents + published abstracts and book chapters. Former Councilor IDSA. Former Associate Editor, Journal of Infectious Diseases/JID.